Lactobacillus reuteri useful as probiotics
The present invention relates to a Lactobacillus reuteri variant from animal sources that inhibits rotavirus infection and other pathogenic microorganisms, as well as being tolerant of gastric and bile acids. Also, this invention relates to a prophylactic and therapeutic composition comprising the same for contributing in many probiotic ways to the host's general health and preventing and treating diseases or conditions associated with rotavirus and other enteric pathogens.
1. Lactobacillus reuteri Probio-16 (Accession No. KCCM 10214), inhibitory of the growth of rotavirus and other pathogenic organisms.
2. A pharmaceutical, veterinary, or alimentary composition comprising an effective amount of probiotic Lactobacillus reuteri Probio-16 as defined in claim 1 and a carrier.
3. The composition of claim 2 wherein the composition is useful for changing the digestive system bacteria in mammals including humans, when fed orally.
4. The composition of claim 2 wherein the composition is useful for the treatment of diarrhea in mammals including humans, when fed orally.
5. A feedstock or food composition including an effective amount of the probiotic composition as defined in claim 2 .
6. A method for reducing the incidence of or treating infectious diarrhea in mammals, including human, said method comprising enterally administering an effective amount of Lactobacillus reuteri Probio-16 as defined in claim 1 .
7. A method for reducing the incidence of or treating infectious diarrhea in mammals, including human, said method comprising enterally administering the probiotic composition defined in claim 2 to said mammals.
8. A method for retarding the onset of or treating an infection caused by rotaviruses in mammals, including human, said method comprising enterally administering an effective amount of Lactobacillus reuteri Probio-16 as defined in claim 1 .
9. A method for retarding the onset of or treating an infection caused by rotaviruses in mammals, including human, said method comprising enterally administering the probiotic composition defined in claim 2 to said mammals.